Phreesia Inc Q2 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Anne Samuel - JPMorgan - Analyst : Hi, guys. Congrats on a great quarter and thanks for taking the questions. I was hoping you could maybe provide a little bit more detail on the social determinants of health announcement. What kind of implications that might have on the cross-sell opportunity going forward?

Question: Anne Samuel - JPMorgan - Analyst : Great, and then just one on the revenue line. You know, your revenue was slightly better than our expectations this quarter. I was just hoping maybe you could speak to what drove some of that upside. And then just how to think about how that will flow through to the back half of the year. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. SEPTEMBER 10, 2019 / 12:30PM, PHR.N - Q2 2020 Phreesia Inc Earnings Call

Question: Anne Samuel - JPMorgan - Analyst : That's very helpful color. Thanks, guys.

Question: Ryan Daniels - William Blair & Company - Analyst : Good morning, guys. Thanks for taking the question. Congrats on a strong quarter out of the box. I wanted to follow up. Tom, you had mentioned partner integration costs. I am curious if you can provide any color on the work that you are doing with Epic and Cerner integration activities. And maybe how that is assisting in either the new sales or the pipeline or even customer retention. And if it is maybe too early to see those benefits manifest, maybe what your expectations would be as those integrations develop.

Question: Ryan Daniels - William Blair & Company - Analyst : Okay. And maybe something you didn't mention, but an update on the work you are doing on the inpatient facilities. I know you have got a partnership with R1. Based on their public comments, it seems like they are rolling that out at some fairly large acute care hospitals. And I know it hasn't been a core focus in the past, but it seems like an interesting novel TAM for you to target. So Chaim, maybe you can talk a little bit about that market opportunity and kind of what you are seeing there. Thanks. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. SEPTEMBER 10, 2019 / 12:30PM, PHR.N - Q2 2020 Phreesia Inc Earnings Call

Question: Ryan Daniels - William Blair & Company - Analyst : All right. Thanks for all the color, guys. Congrats again on the strong start.

Question: Jamie Stockton - Wells Fargo Securities, LLC - Analyst : Good morning. So I guess maybe just following up on Ryan's question about Cerner and Epic. If we kind of take a step back and look at the broader environment, NextGen talked about maybe some trend toward subscription deals that is impacting them a little bit. You got, I'm sure, some noise around Athena and GE and putting those businesses together. Can you just give us a sense of what the environment feels like right now? If there is anything that has changed? Just anything on that front would be great.

Question: Jamie Stockton - Wells Fargo Securities, LLC - Analyst : That's great. And then maybe just on the life sciences business, I hear that you guys had really solid execution during the quarter and got some campaigns maybe done a little sooner than you might have otherwise expected. Can you talk about what your approach is to that business, let's say, over the next two or three years? Whether or not you are trying to grow it from this point? Just anything that you are doing as far as trying to elevate what has been kind of a flat business for the last few years? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. SEPTEMBER 10, 2019 / 12:30PM, PHR.N - Q2 2020 Phreesia Inc Earnings Call

Question: Jamie Stockton - Wells Fargo Securities, LLC - Analyst : Okay, thank you.

Question: Sean Wieland - Piper Jaffray & Co. - Analyst : Thank you. Good morning. On the revenue per client metric that you are giving us, can you break that down into how much of that is being driven by -- or natural organic growth of the client and their business growing? How much of that is increased penetration of the existing products that they bought? And how much of that is uptake on the new products and what new products are they taking up?

Question: Sean Wieland - Piper Jaffray & Co. - Analyst : Can you call out one or two of the -- what about calling out some specific apps that they are taking up?

Question: Sean Wieland - Piper Jaffray & Co. - Analyst : All right. Thank you. And then on the life sciences business, so I hear you on the early delivery. Is there a delta in the cost structure when you deliver these campaigns earlier? And in these agreements, who has controlled the cadence of these messages? Is it you or is it the client?

Question: Sean Wieland - Piper Jaffray & Co. - Analyst : Yes. Just wanted to know who is really controlling the cadence of how these messages goes out. Is it you, is it the life sciences client, is it the provider?

Question: Sean Wieland - Piper Jaffray & Co. - Analyst : All right. Thank you very much.